| scholarly article | Q13442814 |
| P50 | author | Walter Kolch | Q30504262 |
| Jens Rauch | Q37837239 | ||
| P2093 | author name string | Shannon Lee | |
| P2860 | cites work | Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency | Q90460706 |
| Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells | Q90522692 | ||
| RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling | Q90596702 | ||
| Epigenetic mechanisms as a new approach in cancer treatment: An updated review | Q90786734 | ||
| Targeting oncogenic Raf protein-serine/threonine kinases in human cancers | Q91004972 | ||
| MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas | Q91311561 | ||
| Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway | Q91433780 | ||
| USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer | Q91698025 | ||
| Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway | Q91725276 | ||
| Targeting ERK1/2 protein-serine/threonine kinases in human cancers | Q91834485 | ||
| CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies | Q91877701 | ||
| Principles and mechanisms of non-genetic resistance in cancer | Q91934228 | ||
| ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression | Q92287712 | ||
| Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status | Q92379393 | ||
| HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy | Q93109391 | ||
| Turning foes to friends: targeting cancer-associated fibroblasts | Q93336606 | ||
| ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis | Q93382033 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain | Q24308838 | ||
| Raf family kinases: old dogs have learned new tricks | Q24316181 | ||
| SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells | Q24338861 | ||
| A decade of exploring the cancer epigenome — biological and translational implications | Q24614467 | ||
| The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset | Q24625220 | ||
| Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases | Q24632768 | ||
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells | Q24648994 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships | Q26741279 | ||
| Epigenetic modulators, modifiers and mediators in cancer aetiology and progression | Q26766149 | ||
| JNK signalling in cancer: in need of new, smarter therapeutic targets | Q27023869 | ||
| Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond | Q27026323 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition | Q27852017 | ||
| Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers | Q27852116 | ||
| Advance in the study on p38 MAPK mediated drug resistance in leukemia | Q28071983 | ||
| Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation | Q28131755 | ||
| Quercetin Suppresses Drug-Resistant Spheres via the p38 MAPK–Hsp27 Apoptotic Pathway in Oral Cancer Cells | Q28485142 | ||
| p38 MAP kinases in the heart | Q28603117 | ||
| Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1 | Q28655621 | ||
| Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis | Q29547567 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| Cancer epigenetics: from mechanism to therapy | Q29614799 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis | Q29615683 | ||
| Mechanisms of cancer drug resistance | Q29615849 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Metabolic reprogramming: a cancer hallmark even warburg did not anticipate | Q29617612 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. | Q39813618 | ||
| An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. | Q39928890 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles | Q40130442 | ||
| Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells | Q40571427 | ||
| p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor | Q40575095 | ||
| Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells | Q41467621 | ||
| Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction | Q41598068 | ||
| CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. | Q41611914 | ||
| Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. | Q41752617 | ||
| Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties | Q42078200 | ||
| Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells. | Q42183993 | ||
| ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells | Q42211295 | ||
| The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier | Q42773975 | ||
| Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 | Q42825163 | ||
| Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. | Q43612255 | ||
| Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance | Q45347095 | ||
| A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. | Q46093038 | ||
| c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice | Q46507474 | ||
| JNK-signaling: A multiplexing hub in programmed cell death | Q47095837 | ||
| NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. | Q47155954 | ||
| Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation | Q47641089 | ||
| Mathematical modeling and computational prediction of cancer drug resistance | Q47660509 | ||
| New perspectives for targeting RAF kinase in human cancer. | Q47688064 | ||
| PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas | Q47736652 | ||
| Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization | Q49340076 | ||
| Re-activation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer | Q49546274 | ||
| Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors | Q49833715 | ||
| ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway | Q49895996 | ||
| Distinct histone modifications denote early stress-induced drug tolerance in cancer | Q50318225 | ||
| The 2 Faces of JNK Signaling in Cancer. | Q38172163 | ||
| Poised epigenetic states and acquired drug resistance in cancer | Q38254072 | ||
| Natural course and biology of CML. | Q38392667 | ||
| The Stress Kinase p38α as a Target for Cancer Therapy | Q38588220 | ||
| Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells | Q38700781 | ||
| SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. | Q38702971 | ||
| ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. | Q38727826 | ||
| Integrating network reconstruction with mechanistic modeling to predict cancer therapies. | Q38729295 | ||
| c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. | Q38733953 | ||
| Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin | Q38740379 | ||
| The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer | Q38743421 | ||
| Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). | Q38747404 | ||
| Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. | Q38751776 | ||
| BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma | Q38771627 | ||
| Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. | Q38794075 | ||
| Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel. | Q38822178 | ||
| Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects | Q38837384 | ||
| Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through growth differentiation factor 15. | Q38870223 | ||
| IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance | Q38890440 | ||
| Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis | Q38894416 | ||
| HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL | Q38894659 | ||
| Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. | Q39004925 | ||
| Role of the unfolded protein response in tumor cell characteristics and cancer outcome | Q39009190 | ||
| RANK expression on breast cancer cells promotes skeletal metastasis | Q39055979 | ||
| Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy | Q39141380 | ||
| PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. | Q39193337 | ||
| Targeting the unfolded protein response in cancer | Q39232751 | ||
| Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-β. | Q39313190 | ||
| HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway | Q39318996 | ||
| MEK inhibitors in oncology: a patent review (2015-Present). | Q39359514 | ||
| Serine and Functional Metabolites in Cancer. | Q39364297 | ||
| Epigenetic plasticity and the hallmarks of cancer. | Q39448979 | ||
| Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. | Q39647581 | ||
| Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence | Q39674577 | ||
| Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells | Q51004855 | ||
| Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway | Q51564424 | ||
| Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi | Q52590685 | ||
| Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma | Q52591043 | ||
| Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors. | Q52591309 | ||
| Targeting FBPase is an emerging novel approach for cancer therapy. | Q52647812 | ||
| p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis | Q53336933 | ||
| BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. | Q53705974 | ||
| An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential. | Q54110203 | ||
| Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. | Q54348724 | ||
| The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation. | Q54977412 | ||
| MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. | Q54978327 | ||
| Cancer epigenetics: Moving forward. | Q55177661 | ||
| SIRT6 haploinsufficiency induces BRAF melanoma cell resistance to MAPK inhibitors via IGF signalling | Q57010854 | ||
| Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis | Q57160043 | ||
| The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression | Q57184205 | ||
| Toward Minimal Residual Disease-Directed Therapy in Melanoma | Q57188242 | ||
| Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer | Q57736167 | ||
| p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway | Q58326859 | ||
| Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma | Q58547833 | ||
| A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers | Q59326849 | ||
| Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours | Q60683111 | ||
| ONECUT2 is a driver of neuroendocrine prostate cancer | Q60907546 | ||
| Targeting the ERK Signaling Pathway in Melanoma | Q64055352 | ||
| Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies | Q64105358 | ||
| p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2 | Q64377557 | ||
| Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. | Q64958992 | ||
| Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer. | Q64975240 | ||
| Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma | Q88162830 | ||
| Targeting Epigenetics in Cancer | Q89169966 | ||
| Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies | Q89312213 | ||
| AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel | Q90029648 | ||
| Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling | Q90211585 | ||
| Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise | Q90390883 | ||
| Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells | Q33228925 | ||
| EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation | Q33328407 | ||
| Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation | Q33560698 | ||
| Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer | Q33572728 | ||
| Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition | Q33576820 | ||
| Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer | Q33889273 | ||
| Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. | Q33920767 | ||
| Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis | Q33946905 | ||
| The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. | Q34005738 | ||
| p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. | Q34008781 | ||
| Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation | Q34104152 | ||
| Mechanisms and functions of p38 MAPK signalling. | Q34125736 | ||
| V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors | Q34248395 | ||
| Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade | Q34281252 | ||
| Cancer Genetics and Epigenetics: Two Sides of the Same Coin? | Q34287662 | ||
| The dynamic control of signal transduction networks in cancer cells | Q34490200 | ||
| The Warburg Effect: How Does it Benefit Cancer Cells? | Q34509467 | ||
| Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers | Q34615545 | ||
| P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer | Q34675545 | ||
| The role of JNK in the development of hepatocellular carcinoma | Q34691340 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism | Q34742599 | ||
| Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function | Q34745057 | ||
| Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas | Q35018167 | ||
| The Warburg effect: evolving interpretations of an established concept | Q35169587 | ||
| Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma | Q35341639 | ||
| JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. | Q35822826 | ||
| Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils | Q36038823 | ||
| Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. | Q36140332 | ||
| PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition | Q36215920 | ||
| Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib | Q36247858 | ||
| IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. | Q36266768 | ||
| Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy | Q36278239 | ||
| MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms | Q36328021 | ||
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms | Q36338753 | ||
| PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer | Q36437685 | ||
| Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells | Q36476849 | ||
| Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation | Q36531161 | ||
| Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals | Q36738823 | ||
| Interfering with MAP kinase docking interactions: implications and perspective for the p38 route | Q36757177 | ||
| Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells | Q36907149 | ||
| Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation | Q36907156 | ||
| p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells | Q36946749 | ||
| Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation | Q36965134 | ||
| BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition | Q36973111 | ||
| The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer | Q37046602 | ||
| BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma | Q37109564 | ||
| The complexity of mitogen-activated protein kinases (MAPKs) made simple | Q37230945 | ||
| Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells | Q37260512 | ||
| Epigenetic Reprogramming in Cancer | Q37291110 | ||
| In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors | Q37365693 | ||
| Signal integration by JNK and p38 MAPK pathways in cancer development | Q37560607 | ||
| MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition | Q37626175 | ||
| Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. | Q37644414 | ||
| Pathological roles of MAPK signaling pathways in human diseases | Q37676393 | ||
| RETRACTED ARTICLE: JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy | Q37702749 | ||
| Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer | Q37715399 | ||
| Roles of p38 MAPKs in invasion and metastasis | Q37977166 | ||
| Computational approaches for analyzing information flow in biological networks | Q38003247 | ||
| Tumor adaptation and resistance to RAF inhibitors | Q38160738 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | neoplasm | Q1216998 |
| drug resistance | Q12147416 | ||
| MAP kinase signaling system | Q71130435 | ||
| P577 | publication date | 2020-02-07 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity | |
| P478 | volume | 21 |
| Q100490609 | Overview of current targeted therapy in gallbladder cancer | cites work | P2860 |
Search more.